 Attachment enhanced 293 cells |
| In one aspect, the invention provides improved HEK 293 cells, which cells are 293 cells which have ... |
|
| Method for the production of polypeptides |
| The above identified purpose is achieved with the method according to the present invention which ... |
|
| DNA sequences coding for a protein conferring male sterility |
| Thus, in a first aspect the present invention provides recombinant or isolated Nucleic acid which: ... |
|
| Tumor associated nucleic acids and uses therefor |
| OF THE INVENTION The examples which follow show the isolation of nucleic acid molecules which code ... |
|
| Mad-related genes in the human |
| It is an object of the invention to provide a cDNA of the human Smad2 gene. It is another object of ... |
|
| Tumor associated nucleic acids and uses therefor |
| OF THE INVENTION The examples which follow show the isolation of nucleic acid molecules which code ... |
|
| Computer-aided display for comparative gene expression |
| The present invention provides innovative systems and methods for visualizing information collected ... |
|
| Polymorphic repeats in human genes |
| OF PARTICULAR EMBODIMENTS OF THE INVENTION The following descriptions of particular embodiments ... |
|
| Semaphorin gene: Semaphorin Y |
| What is claimed is: 1. An isolated nucleic acid molecule comprising a polynucleotide having a ... |
|
|
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
| Details |
Inventors: Erickson, Sharon; Schwall, Ralph; Sliwkowski, Mark; Blattler, Walter;
Assignee: Genentech, Inc. (South San Francisco, CA) Immunogen, Inc. (Cambridge, MA)
Primary Examiner: Helms; Larry R.
Assistant Examiner: Sang; Hong
Attorney, Agent or Firm: Fox; James A. Dreger; Ginger R. Heller Ehrman LLP
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A method for the treatment of a tumor in a mammal, comprising the steps of (i) identifying said tumor as being characterized by overexpression of an ErbB2 receptor and as being a tumor that does not respond, or responds poorly, to treatment with an anti-ErbB2 antibody which binds to the 4D5 epitope and which has a growth inhibitory effect on SK-BR-3 cells, and (ii) administering to a mammal having said tumor a therapeutically effective amount of a conjugate of an anti-ErbB2 antibody which binds to the 4D5 epitope with a maytansinoid.
2.
The method of claim 1 wherein the mammal is human.
3.
The method of claim 1 wherein the anti-ErbB2 antibody is a growth inhibitory antibody effective to inhibit the growth of SK-BR-3 breast tumor cells in vitro.
4.
The method of claim 1 wherein the anti-ErbB2 antibody induces cell death when applied at an effective concentration in vitro to SK-BR-3 cells.
5.
The method of claim 1 wherein the anti-ErbB2 antibody induces apoptosis when applied at an effective concentration in vitro to SK-BR-3 cells.
6.
The method of claim 1 wherein the tumor is cancer.
7.
The method of claim 6 wherein the cancer is selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate and bladder cancer.
8.
The method of claim 7 wherein the cancer is breast cancer.
9.
The method of claim 8 wherein the breast cancer overexpresses ErbB2 at a 2+ level or more.
10.
The method of claim 9 wherein the breast cancer overexpresses ErbB2 at a 3+ level.
11.
The method of claim 10 wherein the breast cancer is a metastatic breast cancer.
12.
The method of claim 10 wherein the antibody has a biological characteristic of a 4D5 monoclonal antibody (ATCC CRL 10463) such that the antibody shows a growth inhibitory effect on SK-BR-3 cells in a manner that is dependent on the ErbB2 expression level and/or blocks binding of monoclonal antibody 4D5 to ErbB2
|
| Related patents |
|
|
Methods for diagnosing early Lyme disease
This invention is based upon the discovery that sera from patients with early Lyme disease contain predominant IgM reactivity to a major 23 kDa protein (p23; also ...
|
|
|
Tango 243 polypeptides and uses thereof
The present invention is based, at least in part, on the discovery of cDNA molecules which encode the TANGO 228, 240, and 243 proteins, all of which are either wholly ...
|
|
|
Dermatophagoides proteins and fragments thereof
What is claimed is: 1. An isolated protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:18 and SEQ ID NO:21. 2. A ...
|
|
|
Tuberculin active proteins and peptides from the cells of tubercle bacilli
What is claimed is: 1. A tuberculin active simple protein from Mycobacterium tuberculosis strain Aoyama B which is characterized by the following amino acid sequence: ##E...
|
|
|
Therapy for injured muscles
We claim: 1. A method for treating an injured muscle, the method comprising the step of local administration of a therapeutically effective amount of a botulinum toxin ...
|
|
|
Secreted and transmembrane polypeptides and nucleic acids encoding the same
1. PRO1560 A cDNA clone (DNA19902-1669) has been identified that encodes a novel polypeptide believed to be a novel member of the tetraspan family, designated in the ...
|
|
|
HIV-specific cytotoxic T-cell responses
OF INVENTION The inventors have found that two nanomer peptides, designated CLP-177 (SEQ ID NO:2) and CLP-72 (SEQ ID NO:8), a hexamer designated CLP-178 (SEQ ID NO:3), ...
|
|
|
Method of immunomodulatory treatment of insulin dependent diabetes mellitus using mycobacterial cell wall compositions
OF PREFERRED EMBODIMENTS The present invention contemplates a method of immunomodulatory therapy in a mammal said method comprising administering to said mammal an ...
|
|
|
Susceptibility mutation for breast and ovarian cancer
OF THE PREFERRED EMBODIMENTS The present invention is based on the discovery of a two base pair deletion of nucleotides 3888 and 3889 of the published BRCA1 cDNA ...
|
|
|
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
The present invention provides a herpetic virus selected from the group consisting of neurotrophic herpes viruses, T-lymphotrophic viruses, and B-lymphotrophic viruses ...
|
|
|
Drugs 
